Literature DB >> 18793961

Treatment planning study to determine potential benefit of intensity-modulated radiotherapy versus conformal radiotherapy for unresectable hepatic malignancies.

Cynthia L Eccles1, Jean-Pierre Bissonnette, Tim Craig, Mojgan Taremi, Xia Wu, Laura A Dawson.   

Abstract

PURPOSE: To compare intensity-modulated radiotherapy (IMRT) with conformal RT (CRT) for hypofractionated isotoxicity liver RT and explore dose escalation using IMRT for the same/improved nominal risk of liver toxicity in a treatment planning study. METHODS AND MATERIALS: A total of 26 CRT plans were evaluated. Prescription doses (24-54 Gy within six fractions) were individualized on the basis of the effective liver volume irradiated maintaining < or =5% risk of radiation-induced liver disease. The dose constraints included bowel (0.5 cm(3)) and stomach (0.5 cm(3)) to < or =30 Gy, spinal cord to < or =25 Gy, and planning target volume (PTV) to < or =140% of the prescribed dose. Two groups were evaluated: (1) PTV overlapping or directly adjacent to serial functioning normal tissues (n = 14), and (2) the liver as the dose-limiting normal tissue (n = 12). IMRT plans using direct machine parameter optimization maintained the CRT plan beam arrangements, an estimated radiation-induced liver disease risk of 5%, and underwent dose escalation, if all normal tissue constraints were maintained.
RESULTS: IMRT improved PTV coverage in 19 of 26 plans (73%). Dose escalation was feasible in 9 cases by an average of 3.8 Gy (range, 0.6-13.2) in six fractions. Three of seven plans without improved PTV coverage had small gross tumor volumes (< or =105 cm(3)) already receiving 54 Gy, the maximal prescription dose allowed. In the remaining cases, the PTV range was 9.6-689 cm(3); two had overlapped organs at risk; and one had four targets. IMRT did not improve these plans owing to poor target coverage (n = 2) and nonliver (n = 2) dose limits.
CONCLUSION: Direct machine parameter optimization IMRT improved PTV coverage while maintaining normal tissue tolerances in most CRT liver plans. Dose escalation was possible in a minority of patients.

Entities:  

Mesh:

Year:  2008        PMID: 18793961     DOI: 10.1016/j.ijrobp.2008.06.1496

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  18 in total

1.  RapidArc vs intensity-modulated radiation therapy for hepatocellular carcinoma: a comparative planning study.

Authors:  J M Park; K Kim; E K Chie; C H Choi; S J Ye; S W Ha
Journal:  Br J Radiol       Date:  2012-07       Impact factor: 3.039

Review 2.  Technical advances in external radiotherapy for hepatocellular carcinoma.

Authors:  Shin-Hyung Park; Jae-Chul Kim; Min Kyu Kang
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

3.  Accumulated dose in liver stereotactic body radiotherapy: positioning, breathing, and deformation effects.

Authors:  Michael Velec; Joanne L Moseley; Tim Craig; Laura A Dawson; Kristy K Brock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-28       Impact factor: 7.038

4.  Effect of breathing motion on radiotherapy dose accumulation in the abdomen using deformable registration.

Authors:  Michael Velec; Joanne L Moseley; Cynthia L Eccles; Tim Craig; Michael B Sharpe; Laura A Dawson; Kristy K Brock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-21       Impact factor: 7.038

Review 5.  Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma.

Authors:  Thomas B Brunner; Cynthia L Eccles
Journal:  Strahlenther Onkol       Date:  2010-11-30       Impact factor: 3.621

6.  Stereotactic body radiation therapy (SBRT) for adrenal metastases : a feasibility study of advanced techniques with modulated photons and protons.

Authors:  Marta Scorsetti; Pietro Mancosu; Piera Navarria; Angelo Tozzi; Simona Castiglioni; Elena Clerici; Giacomo Reggiori; Francesca Lobefalo; Antonella Fogliata; Luca Cozzi
Journal:  Strahlenther Onkol       Date:  2011-03-25       Impact factor: 3.621

7.  Radiotherapy with volumetric modulated arc therapy for hepatocellular carcinoma patients ineligible for surgery or ablative treatments.

Authors:  P-M Wang; W-C Hsu; N-N Chung; F-L Chang; A Fogliata; L Cozzi
Journal:  Strahlenther Onkol       Date:  2013-02-20       Impact factor: 3.621

8.  Dose escalated liver stereotactic body radiation therapy at the mean respiratory position.

Authors:  Michael Velec; Joanne L Moseley; Laura A Dawson; Kristy K Brock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-08       Impact factor: 7.038

9.  Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases--clinical results.

Authors:  Judit Boda-Heggemann; Dietmar Dinter; Christel Weiss; Anian Frauenfeld; Kerstin Siebenlist; Ulrike Attenberger; Martine Ottstadt; Frank Schneider; Ralf-Dieter Hofheinz; Frederik Wenz; Frank Lohr
Journal:  Radiat Oncol       Date:  2012-06-18       Impact factor: 3.481

10.  Four-dimensional CT-based evaluation of volumetric modulated arc therapy for abdominal lymph node metastasis from hepatocellular carcinoma.

Authors:  Li Zhang; Mian Xi; Xiao-Wu Deng; Qiao-Qiao Li; Xiao-Yan Huang; Meng-Zhong Liu
Journal:  J Radiat Res       Date:  2012-06-28       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.